Sign In
Buy MED
MEDIFAST Earnings Calls
| Release date | May 04, 2026 |
| EPS estimate | -$0.550 |
| EPS actual | -$0.190 |
| EPS Surprise | 65.45% |
| Revenue estimate | 69.2M |
| Revenue actual | 76.044M |
| Revenue Surprise | 9.89% |
| Release date | Feb 17, 2026 |
| EPS estimate | -$0.760 |
| EPS actual | -$0.550 |
| EPS Surprise | 27.63% |
| Revenue estimate | 71.4M |
| Revenue actual | 75.096M |
| Revenue Surprise | 5.18% |
| Release date | Nov 03, 2025 |
| EPS estimate | -$0.0100 |
| EPS actual | -$0.210 |
| EPS Surprise | -2,000.00% |
| Revenue estimate | 71.4M |
| Revenue actual | 89.409M |
| Revenue Surprise | 25.22% |
| Release date | Aug 04, 2025 |
| EPS estimate | -$0.300 |
| EPS actual | $0.0400 |
| EPS Surprise | 113.33% |
| Revenue estimate | 93.8M |
| Revenue actual | 105.555M |
| Revenue Surprise | 12.53% |
Last 4 Quarters for MEDIFAST
Below you can see how MED performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 04, 2025 |
| Price on release | $13.51 |
| EPS estimate | -$0.300 |
| EPS actual | $0.0400 |
| EPS surprise | 113.33% |
| Date | Price |
|---|---|
| Jul 29, 2025 | $14.32 |
| Jul 30, 2025 | $14.02 |
| Jul 31, 2025 | $13.77 |
| Aug 01, 2025 | $13.75 |
| Aug 04, 2025 | $13.51 |
| Aug 05, 2025 | $13.07 |
| Aug 06, 2025 | $12.96 |
| Aug 07, 2025 | $12.74 |
| Aug 08, 2025 | $12.85 |
| 4 days before | -5.66% |
| 4 days after | -4.89% |
| On release day | -3.26% |
| Change in period | -10.27% |
| Release date | Nov 03, 2025 |
| Price on release | $11.88 |
| EPS estimate | -$0.0100 |
| EPS actual | -$0.210 |
| EPS surprise | -2,000.00% |
| Date | Price |
|---|---|
| Oct 28, 2025 | $12.73 |
| Oct 29, 2025 | $12.18 |
| Oct 30, 2025 | $12.14 |
| Oct 31, 2025 | $12.02 |
| Nov 03, 2025 | $11.88 |
| Nov 04, 2025 | $11.98 |
| Nov 05, 2025 | $12.18 |
| Nov 06, 2025 | $11.80 |
| Nov 07, 2025 | $11.93 |
| 4 days before | -6.68% |
| 4 days after | 0.421% |
| On release day | 0.84% |
| Change in period | -6.28% |
| Release date | Feb 17, 2026 |
| Price on release | $10.80 |
| EPS estimate | -$0.760 |
| EPS actual | -$0.550 |
| EPS surprise | 27.63% |
| Date | Price |
|---|---|
| Feb 10, 2026 | $11.14 |
| Feb 11, 2026 | $10.85 |
| Feb 12, 2026 | $10.81 |
| Feb 13, 2026 | $10.77 |
| Feb 17, 2026 | $10.80 |
| Feb 18, 2026 | $10.71 |
| Feb 19, 2026 | $10.62 |
| Feb 20, 2026 | $10.63 |
| Feb 23, 2026 | $10.60 |
| 4 days before | -3.05% |
| 4 days after | -1.85% |
| On release day | -0.83% |
| Change in period | -4.85% |
| Release date | May 04, 2026 |
| Price on release | $10.63 |
| EPS estimate | -$0.550 |
| EPS actual | -$0.190 |
| EPS surprise | 65.45% |
| Date | Price |
|---|---|
| Apr 28, 2026 | $10.81 |
| Apr 29, 2026 | $10.92 |
| Apr 30, 2026 | $10.87 |
| May 01, 2026 | $10.91 |
| May 04, 2026 | $10.63 |
| May 05, 2026 | $13.02 |
| May 06, 2026 | $12.69 |
| May 07, 2026 | $12.69 |
| May 08, 2026 | $12.59 |
| 4 days before | -1.67% |
| 4 days after | 18.44% |
| On release day | 22.48% |
| Change in period | 16.47% |
MEDIFAST Earnings Call Transcript Summary of Q1 2026
Medifast reported Q1 2026 revenue of $76M (down 34.3% YoY) and a net loss of $2.1M ($0.19 per share). Active earning coaches declined ~45% YoY to ~14,000, driven by GLP-1 adoption and a deliberate shift to a more productive coach leadership structure. Offsetting this, coach productivity rose 19% YoY (16% sequentially), the largest quarterly increase in five years, and management sees this as an early leading indicator of stabilization and future growth. The company is executing a strategic repositioning from weight loss to a broader metabolic health focus built on “metabolic synchronization” science, plans to launch a new three-phase metabolic product system later in 2026 (pilot showing encouraging feedback), and is simplifying coach tools and referral programs. Cost realignment actions are expected to yield >$30M in future savings; gross margin and SG&A improvements are expected to begin showing in the back half of 2026 with a targeted move toward profitability starting in Q4 2026. Balance sheet remains strong with ~$169M of cash, cash equivalents and investments and no debt. Q2 2026 revenue guidance is $60M–$80M (loss per share $0.50–$1.00); full-year 2026 revenue guidance is $270M–$300M (loss per share $1.05–$2.75). CEO Daniel Chard will step down as CEO effective June 1 but will remain chairman of the board; Nicholas Johnson is positioned as the operational leader driving the metabolic-health strategy.
